tiprankstipranks
Trending News
More News >
COSMO Pharmaceuticals N.V. (DE:C43)
FRANKFURT:C43
Germany Market
Advertisement

COSMO Pharmaceuticals N.V. (C43) Financial Statements

Compare
2 Followers

COSMO Pharmaceuticals N.V. Financial Overview

COSMO Pharmaceuticals N.V.'s market cap is currently CHF1.12B. The company's EPS TTM is €8.292; its P/E ratio is 8.16; and it has a dividend yield of 3.07%. COSMO Pharmaceuticals N.V. is scheduled to report earnings on March 20, 2025, and the estimated EPS forecast is €3.86. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue€ 266.79M€ 92.78M€ 102.09M€ 65.07M€ 60.95M
Gross Profit€ 246.92M€ 53.44M€ 83.33M€ 49.93M€ 50.51M
Operating Income€ 148.88M€ 6.15M€ 28.06M€ 33.11M€ 2.06M
EBITDA€ 165.71M€ 19.70M€ 47.49M€ 40.48M€ 7.84M
Net Income€ 133.24M€ -4.93M€ 17.23M€ 21.67M€ -7.90M
Balance Sheet
Cash & Short-Term Investments€ 142.96M€ 50.27M€ 240.95M€ 222.21M€ 212.85M
Total Assets€ 646.77M€ 553.98M€ 759.59M€ 805.56M€ 596.16M
Total Debt€ 2.20M€ 1.84M€ 173.60M€ 169.92M€ 168.14M
Net Debt€ -42.09M€ -48.44M€ -12.23M€ -28.64M€ -17.79M
Total Liabilities€ 141.68M€ 124.94M€ 295.80M€ 292.88M€ 196.04M
Stockholders' Equity€ 498.33M€ 422.16M€ 456.93M€ 505.28M€ 400.13M
Cash Flow
Free Cash Flow€ 156.76M€ 18.31M€ 25.92M€ 4.11M€ 4.90M
Operating Cash Flow€ 162.41M€ 22.71M€ 33.23M€ 12.61M€ 12.98M
Investing Cash Flow€ -128.88M€ 42.30M€ 1.69M€ 24.86M€ 75.45M
Financing Cash Flow€ -40.22M€ -211.27M€ -46.13M€ -27.25M€ -11.88M
Currency in EUR

COSMO Pharmaceuticals N.V. Earnings and Revenue History

COSMO Pharmaceuticals N.V. Debt to Assets

COSMO Pharmaceuticals N.V. Cash Flow

COSMO Pharmaceuticals N.V. Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis